Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gupta, Sounak ^a   Hau, Andrew M ^a   Beach, Jordan R ^b   Harwalker, Jyoti ^b   Mantuano, Elisabetta ^a   Gonias, Steven L ^a   Egelhoff, Thomas T ^b   Hansel, Donna E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIPROTEIN COMPLEX; RAC1 PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

BLADDER TUMOR; CELL MOTION; DISEASE COURSE; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84894239320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081081     Document Type: Article

References (38)

1. American Cancer Society (2013). Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
3. Eble JN SG, Epstein JI, Sesterhenn IA editors (2004) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press.
4. Watts KE, Montironi R, Mazzucchelli R, van der Kwast T, Osunkoya AO et al. (2012) Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma. Urology 80: 361-366. doi:10.1016/j.urology.2012. 04.010. PubMed: 22857755.
5. Kamat AM, Mathew P (2011) Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 25: 951-958. p. 960.
6. Cheng T, Roth B, Choi W, Black PC, Dinney C et al. (2013) Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLOS ONE 8: e57284. doi:10.1371/journal.pone.0057284. PubMed: 23468956.
7. Zhu Z, Zhu Z, Pang Z, Xing Y, Wan F et al. (2013) Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer. Int J Oncol 42: 1271-1278. PubMed: 23403865.
8. Sun CH, Chang YH, Pan CC (2011) Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054-1063. doi:10.1111/j.1365-2559.2011.03856.x. PubMed: 21707707.
9. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S et al. (2010) Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072. doi:10.2353/ajpath. 2010.090872. PubMed: 20395440.
10. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71: 3246-3256. doi:10.1158/0008-5472. CAN-10-4058. PubMed: 21430067.
11. Masri J, Bernath A, Martin J, Jo OD, Vartanian R et al. (2007) mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67: 11712-11720. doi:10.1158/0008-5472.CAN- 07-2223. PubMed: 18089801.
12. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128. doi:10.1038/ncb1183. PubMed: 15467718.
13. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302. doi:10.1016/j.cub.2004.06.054. PubMed: 15268862.
14. Yang Q, Inoki K, Ikenoue T, Guan KL (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20: 2820-2832. doi:10.1101/gad.1461206. PubMed: 17043309.
15. Zhou H, Huang S (2011) Role of mTOR signaling in tumor cell motility. Invasion and Metastasis - Curr Protein Pept Sci 12: 30-42. doi:10.2174/ 138920311795659407.
16. Liu L, Das S, Losert W, Parent CA (2010) mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev Cell 19: 845-857. doi:10.1016/j.devcel.2010.11.004. PubMed: 21145500.
17. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R (2012) TGF-beta-induced activation of mTOR complex 2 drives epithelialmesenchymal transition and cell invasion. J Cell Sci 125: 1259-1273. doi:10.1242/jcs.095299. PubMed: 22399812.
18. Li H, Lin J, Wang X, Yao G, Wang L et al. (2012) Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat 134: 1057-1066. doi:10.1007/s10549-012-2036-2. PubMed: 22476852.
19. Beach JR, Hussey GS, Miller TE, Chaudhury A, Patel P et al. (2011) Myosin II isoform switching mediates invasiveness after TGF-beta-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 108: 17991-17996. doi:10.1073/pnas.1106499108. PubMed: 22025714.
20. Breckenridge MT, Dulyaninova NG, Egelhoff TT (2009) Multiple regulatory steps control mammalian nonmuscle myosin II assembly in live cells. Mol Biol Cell 20: 338-347. doi:10.1091/mbc.E08-04-0372. PubMed: 18971378.
21. Al Hussain TO, Akhtar M (2013) Molecular basis of urinary bladder cancer. Adv Anat Pathol 20: 53-60. doi:10.1097/PAP.0b013e31827bd0ec. PubMed: 23232572.
22. Kim J, Ji M, DiDonato JA, Rackley RR, Kuang M et al. (2011) An hTERT-immortalized human urothelial cell line that responds to antiproliferative factor. In Vitro Cell Dev Biol Anim 47: 2-9. doi:10.1007/s11626-011-9417-4. PubMed: 21136194.
23. Schaller MD (2001) Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472. doi:10.1038/sj.onc.1204786. PubMed: 11607845.
24. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA et al. (2004) PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 23: 6788-6797. doi:10.1038/sj.onc.1207599. PubMed: 15273733.
25. Chang F, Lemmon C, Lietha D, Eck M, Romer L (2011) Tyrosine phosphorylation of Rac1: a role in regulation of cell spreading. PLOS ONE 6: e28587. doi:10.1371/journal.pone.0028587. PubMed: 22163037.
26. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35. doi:10.1038/nrm3025. PubMed: 21157483.
27. Gan X, Wang J, Su B, Wu D (2011) Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 286: 10998-11002. doi:10.1074/jbc.M110.195016. PubMed: 21310961.
28. Zinzalla V, Stracka D, Oppliger W, Hall MN (2011) Activation of mTORC2 by association with the ribosome. Cell 144: 757-768. doi:10.1016/j.cell.2011.02. 014. PubMed: 21376236.
29. Koromilas AE (2011) Negative regulation of mTORC2 by glycogen synthase kinase-3beta: an adaptive process to stress with an anticancer therapeutic potential? Future Oncol 7: 845-848. doi:10.2217/fon.11.59. PubMed: 21732756.
30. Wu YT, Ouyang W, Lazorchak AS, Liu D, Shen HM et al. (2011) mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. J Biol Chem 286: 14190-14198. doi:10.1074/jbc.M111.219923. PubMed: 21321111.
31. Huang W, Zhu PJ, Zhang S, Zhou H, Stoica L et al. (2013) mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci 16: 441-448. doi:10.1038/nn.3351. PubMed: 23455608.
32. Liu L, Luo Y, Chen L, Shen T, Xu B et al. (2010) Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 285: 38362-38373. doi:10.1074/jbc.M110.141168. PubMed: 20937815.
33. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP et al. (2000) Rho family proteins in cell adhesion and cell migration. Eur J Cancer 36: 1269-1274. doi:10.1016/S0959-8049(00)00091-5. PubMed: 10882865.
34. Ching CB, Hansel DE (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 90: 1406-1414. doi:10.1038/labinvest.2010.133. PubMed: 20661228.
35. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R et al. (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69: 3256-3261. doi:10.1158/0008-5472.CAN-08-4055. PubMed: 19351834.
36. Yu L, Yuan X, Wang D, Barakat B, Williams ED et al. (2013) Selective regulation of p38beta protein and signaling by integrin-linked kinase mediates bladder cancer cell migration. Oncogene.
37. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M et al. (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618-1624. doi:10.1158/0008-5472.CAN-07-5869. PubMed: 18339839.
38. Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42: 50-61. doi:10.1016/j.molcel.2011.03.017. PubMed: 21474067.